Keratin 5 Overexpression is Associated with Serous Ovarian Cancer Recurrence and Chemotherapy Resistance

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Feb 2

PMID 28147318

Citations 34

Authors

Carmela Ricciardelli

Noor A Lokman

Carmen E Pyragius

Miranda P Ween

Anne M Macpherson

Andrew Ruszkiewicz

Peter Hoffmann

Martin K Oehler

Affiliations

Soon will be listed here.

Abstract

This study investigated the clinical significance of keratin 5 and 6 expression in serous ovarian cancer progression and chemotherapy resistance. KRT5 and KRT6 (KRT6A, KRT6B & KRT6C) gene expression was assessed in publically available serous ovarian cancer data sets, ovarian cancer cell lines and primary serous ovarian cancer cells. Monoclonal antibodies which detect both K5/6 or only K5 were used to assess protein expression in ovarian cancer cell lines and a cohort of high grade serous ovarian carcinomas at surgery (n = 117) and after neoadjuvant chemotherapy (n = 21). Survival analyses showed that high KRT5 mRNA in stage III/IV serous ovarian cancers was significantly associated with reduced progression-free (HR 1.38, P < 0.0001) and overall survival (HR 1.28, P = 0.013) whilst high KRT6 mRNA was only associated with reduced progression-free survival (HR 1.2, P = 0.031). Both high K5/6 (≥ 10%, HR 1.78 95% CI; 1.03-2.65, P = 0.017) and high K5 (≥ 10%, HR 1.90, 95% CI; 1.12-3.19, P = 0.017) were associated with an increased risk of disease recurrence. KRT5 but not KRT6C mRNA expression was increased in chemotherapy resistant primary serous ovarian cancer cells compared to chemotherapy sensitive cells. The proportion of serous ovarian carcinomas with high K5/6 or high K5 immunostaining was significantly increased following neoadjuvant chemotherapy. K5 can be used to predict serous ovarian cancer prognosis and identify cancer cells that are resistant to chemotherapy. Developing strategies to target K5 may therefore improve serous ovarian cancer survival.

Citing Articles

Pre-ciliated tubal epithelial cells are prone to initiation of high-grade serous ovarian carcinoma.

Flesken-Nikitin A, Ralston C, Fu D, De Micheli A, Phuong D, Harlan B Nat Commun. 2024; 15(1):8641.

PMID: 39366996 PMC: 11452611. DOI: 10.1038/s41467-024-52984-1.

Keratins 6, 16, and 17 in Health and Disease: A Summary of Recent Findings.

Romashin D, Tolstova T, Varshaver A, Kozhin P, Rusanov A, Luzgina N Curr Issues Mol Biol. 2024; 46(8):8627-8641.

PMID: 39194725 PMC: 11352355. DOI: 10.3390/cimb46080508.

Cell-intrinsic platinum response and associated genetic and gene expression signatures in ovarian cancer cell lines and isogenic models.

Adams K, Wendt J, Wood J, Olson S, Moreno R, Jin Z bioRxiv. 2024; .

PMID: 39131380 PMC: 11312449. DOI: 10.1101/2024.07.26.605381.

Engineered CAR-T cells targeting the non-functional P2X purinoceptor 7 (P2X7) receptor as a novel treatment for ovarian cancer.

Bandara V, Niktaras V, Willett V, Chapman H, Lokman N, Macpherson A Clin Transl Immunology. 2024; 13(5):e1512.

PMID: 38800555 PMC: 11116765. DOI: 10.1002/cti2.1512.

Disabled-2: a protein up-regulated by high molecular weight hyaluronan has both tumor promoting and tumor suppressor roles in ovarian cancer.

Price Z, Lokman N, Sugiyama M, Koya Y, Yoshihara M, Oehler M Cell Mol Life Sci. 2023; 80(11):320.

PMID: 37815603 PMC: 10564841. DOI: 10.1007/s00018-023-04972-9.

References

Grimm S, Bu W, Longley M, Roop D, Li Y, Rosen J . Keratin 6 is not essential for mammary gland development. Breast Cancer Res. 2006; 8(3):R29. PMC: 1557733. DOI: 10.1186/bcr1504. View

Ricciardelli C, Lokman N, Cheruvu S, Tan I, Ween M, Pyragius C . Transketolase is upregulated in metastatic peritoneal implants and promotes ovarian cancer cell proliferation. Clin Exp Metastasis. 2015; 32(5):441-55. DOI: 10.1007/s10585-015-9718-1. View

Van Batavia J, Yamany T, Molotkov A, Dan H, Mansukhani M, Batourina E . Bladder cancers arise from distinct urothelial sub-populations. Nat Cell Biol. 2014; 16(10):982-91, 1-5. DOI: 10.1038/ncb3038. View

Rogers M, Edler L, Winter H, Langbein L, Beckmann I, Schweizer J . Characterization of new members of the human type II keratin gene family and a general evaluation of the keratin gene domain on chromosome 12q13.13. J Invest Dermatol. 2005; 124(3):536-44. DOI: 10.1111/j.0022-202X.2004.23530.x. View

Ricciardelli C, Lokman N, Ween M, Oehler M . WOMEN IN CANCER THEMATIC REVIEW: Ovarian cancer-peritoneal cell interactions promote extracellular matrix processing. Endocr Relat Cancer. 2016; 23(11):T155-T168. DOI: 10.1530/ERC-16-0320. View

Lokman N, Elder A, Ricciardelli C, Oehler M . Chick chorioallantoic membrane (CAM) assay as an in vivo model to study the effect of newly identified molecules on ovarian cancer invasion and metastasis. Int J Mol Sci. 2012; 13(8):9959-9970. PMC: 3431839. DOI: 10.3390/ijms13089959. View

Lokman N, Elder A, Ween M, Pyragius C, Hoffmann P, Oehler M . Annexin A2 is regulated by ovarian cancer-peritoneal cell interactions and promotes metastasis. Oncotarget. 2013; 4(8):1199-211. PMC: 3787151. DOI: 10.18632/oncotarget.1122. View

Karantza V . Keratins in health and cancer: more than mere epithelial cell markers. Oncogene. 2010; 30(2):127-38. PMC: 3155291. DOI: 10.1038/onc.2010.456. View

Inanc M, Ozkan M, Karaca H, Berk V, Bozkurt O, Duran A . Cytokeratin 5/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancer. Med Oncol. 2013; 31(1):801. DOI: 10.1007/s12032-013-0801-7. View

10.

Wauters C, Smedts F, Gerrits L, Bosman F, Ramaekers F . Keratins 7 and 20 as diagnostic markers of carcinomas metastatic to the ovary. Hum Pathol. 1995; 26(8):852-5. DOI: 10.1016/0046-8177(95)90006-3. View

11.

Nielsen T, Hsu F, Jensen K, Cheang M, Karaca G, Hu Z . Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004; 10(16):5367-74. DOI: 10.1158/1078-0432.CCR-04-0220. View

12.

Bocker W, Moll R, Poremba C, Holland R, van Diest P, Dervan P . Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: a new cell biological concept. Lab Invest. 2002; 82(6):737-46. DOI: 10.1097/01.lab.0000017371.72714.c5. View

13.

Perou C, Sorlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C . Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-52. DOI: 10.1038/35021093. View

14.

Ostergaard M, Rasmussen H, Nielsen H, Vorum H, Orntoft T, Wolf H . Proteome profiling of bladder squamous cell carcinomas: identification of markers that define their degree of differentiation. Cancer Res. 1997; 57(18):4111-7. View

15.

Schmelz M, Moll R, Hesse U, Prasad A, Gandolfi J, Hasan S . Identification of a stem cell candidate in the normal human prostate gland. Eur J Cell Biol. 2005; 84(2-3):341-54. PMC: 2730953. DOI: 10.1016/j.ejcb.2004.12.019. View

16.

Liu M, Mor G, Cheng H, Xiang X, Hui P, Rutherford T . High frequency of putative ovarian cancer stem cells with CD44/CK19 coexpression is associated with decreased progression-free intervals in patients with recurrent epithelial ovarian cancer. Reprod Sci. 2012; 20(5):605-15. PMC: 3635069. DOI: 10.1177/1933719112461183. View

17.

Khayyata S, Yun S, Pasha T, Jian B, McGrath C, Yu G . Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine-needle aspiration specimens. Diagn Cytopathol. 2009; 37(3):178-83. DOI: 10.1002/dc.20975. View

18.

Ring B, Seitz R, Beck R, Shasteen W, Soltermann A, Arbogast S . A novel five-antibody immunohistochemical test for subclassification of lung carcinoma. Mod Pathol. 2009; 22(8):1032-43. DOI: 10.1038/modpathol.2009.60. View

19.

Pallari H, Eriksson J . Intermediate filaments as signaling platforms. Sci STKE. 2006; 2006(366):pe53. DOI: 10.1126/stke.3662006pe53. View

20.

Moran C, Albores-Saavedra J, Suster S . Primary peritoneal mesotheliomas in children: a clinicopathological and immunohistochemical study of eight cases. Histopathology. 2008; 52(7):824-30. DOI: 10.1111/j.1365-2559.2008.03029.x. View